We resolved several suits for persons who developed a sudden form of diabetes while taking the antibiotic Tequin (gatifloxacin), sold by Bristol-Meyers Squibb.
Bristol-Myers stopped marketing Tequin in June 2006 under pressure from the FDA. This followed an article in the prestigious New England Journal of Medicine reporting on many cases of persons who had sudden diabetic comas and dysglycemia. This was all in the setting of many safer antibiotics available to patients at a less expensive price. This reveals that the drug has been associated with both hypoglycemia and hyperglycemia (too little or too much sugar). Either of these conditions can place a person into a coma.
